Figure B. Analytic framework for KQ 3. This figure depicts KQ 3 within the context of the PICOTS. KQ 3 considers the comparative effectiveness and safety of monotherapy or combination therapy for PAH using calcium channel blockers, prostanoids, endothelin antagonists, or phosphodiesterase inhibitors on intermediate-term outcomes (e.g., hemodynamic parameters, dyspnea, 6-minute walk, hospitalization) and long-term outcomes (e.g., functional class, quality of life, right heart failure, transplantation [lung or heart-lung], mortality) as well as adverse effects associated with PAH therapies (e.g., safety of pharmacotherapies and parenteral therapy).

Figure BAnalytic framework for KQ 3

KQ = Key Question; PAH = pulmonary arterial hypertension

From: Executive Summary

Cover of Pulmonary Arterial Hypertension: Screening, Management, and Treatment
Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].
Comparative Effectiveness Reviews, No. 117.
McCrory DC, Coeytaux RR, Schmit KM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.